Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

139.20 +0.02 (+0.01%)

Official Closing Price Updated: 4:10 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

53 54 Next >

AlphaFold’s Five-Year Reign: 3 Million Researchers and the Dawn of a New Biological Era

Today 15:14 EST

In a milestone that cements artificial intelligence as the most potent tool in modern science, Google DeepMind’s AlphaFold has officially surpassed 3 million users worldwide. This achievement coincides...

Via TokenRing AI

Topics Artificial Intelligence Climate Change

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

Today 14:06 EST

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case ↗

Today 5:01 EST

Novartis (NVS) presents a classic value investing case: a financially strong pharmaceutical leader trading at a discount to peers, with high profitability and a solid dividend.

Via Chartmill

The Biological Turing Point: How AlphaFold 3 and the Nobel Prize Redefined the Future of Medicine

December 25, 2025

In the final weeks of 2025, the scientific community is reflecting on a year where the boundary between computer science and biology effectively vanished. The catalyst for this transformation was...

Via TokenRing AI

Topics Artificial Intelligence Initial Public Offering

Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill ↗

December 23, 2025

On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.

Via The Motley Fool

Topics Stocks

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

2 Top Stocks to Buy and Hold for the Long Term ↗

December 22, 2025

Both have crushed the market this year.

Via The Motley Fool

Topics Intellectual Property

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Via Stocktwits

Topics Government World Trade

Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗

December 19, 2025

Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday.

Via Investor's Business Daily

Topics Government Stocks

AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗

December 19, 2025

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

Via Stocktwits

Topics Economy Government

White House Readies Drug Price Deals With AbbVie, Novartis, Roche ↗

December 18, 2025

AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and Medicare payment reforms.

Via Benzinga

Salesforce Stock Rises On BTIG Buy Rating And Novartis Agentforce Deal ↗

December 17, 2025

Salesforce Inc (NYSE:CRM) shares moved higher Wednesday after BTIG kicked off coverage with a Buy rating and a $335 price target, while the company scored a major win with Novartis choosing its...

Via Benzinga

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Via Stocktwits

Topics Government World Trade

Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Financials ↗

December 10, 2025

Novartis (NVS) offers a reliable 3.27% dividend yield, backed by strong profitability, a healthy balance sheet, and a history of consistent payouts.

Via Chartmill

Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder ↗

December 09, 2025

Novartis reports Phase 3 results showing that combining ianalumab with eltrombopag significantly extends disease control and improves sustained platelet response in ITP patients.

Via Benzinga

Can the Vanguard International High Dividend Yield Index Fund ETF Shares Outperform Again in 2026? ↗

December 07, 2025

This low-cost international dividend ETF nearly doubled the S&P 500's return in 2025 -- but replicating that performance will require the stars to align once more.

Via The Motley Fool

Topics ETFs Economy Stocks

Silver Shines as Global Tariff Storm Gathers: A Safe-Haven and Strategic Imperative in 2025

December 09, 2025

As global trade tensions escalate dramatically throughout late 2024 and 2025, marked by a surge in protectionist policies and tit-for-tat tariffs, silver has emerged as a dual-threat asset: a critical...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

This hot biotech stock could have a lot more room to run.

Via The Motley Fool

Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035

December 03, 2025

The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,...

Via MarketMinute

Topics Artificial Intelligence Death Intellectual Property

Morgan Stanley Downgrades Regeneron (REGN) to Equal-Weight, Citing Fair Valuation and Pipeline Scrutiny

December 03, 2025

New York, NY – December 3, 2025 – In a significant move reverberating through the biotechnology sector, investment banking giant Morgan Stanley has downgraded Regeneron Pharmaceuticals (NASDAQ: REGN)...

Via MarketMinute

Topics Intellectual Property

Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound ↗

December 02, 2025

Janux shares plunged after the JANX007 trial update prompted widespread target cuts, even as retail traders framed the selloff as poised for a rebound.

Via Stocktwits

1 No-Brainer International Vanguard ETF to Buy Right Now for Less Than $100 ↗

November 29, 2025

A weakening dollar makes this ETF more appealing.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

2 High-Yielding ETFs That Can Bankroll Your Retirement for Years ↗

November 29, 2025

These funds offer yields that are more than three times the S&P 500 average.

Via The Motley Fool

Topics ETFs Economy Retirement

Why Novartis Stock Topped the Market Today ↗

November 25, 2025

The company has a brand-new product to ship to pharmacies.

Via The Motley Fool

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults ↗

November 25, 2025

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function improvements.

Via Benzinga

Novartis Stock Rises Premarket After FDA Approves First Gene Therapy For Teens And Adults With Muscle-Weakening Disorder ↗

November 25, 2025

FDA cleared Itvisma as the first gene-replacement therapy available to people 2 and older with the rare muscle-weakening condition.

Via Stocktwits

NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Comprehensive Value Investment Analysis ↗

November 24, 2025

Novartis (NVS) appears undervalued with a low P/E ratio, strong profitability, and solid financial health, making it a compelling stock for value investors.

Via Chartmill

Bionique Wins Dual Golds for “Exosome + Probiotic” Breakthrough in Women’s Microbiome Health

November 21, 2025

Via Get News

European Stocks Soar as Strong Earnings Quell 'AI Bubble' Fears

November 20, 2025

European equity markets have experienced a significant resurgence around November 20, 2025, with major indices climbing as robust company results, particularly from the technology sector, have...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗

November 20, 2025

Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline strategy driving growth through 2030.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.